Roche CEO: Future of cancer treatment, AI in Medicine and Trial Challenges
Listen to the original audio · Transcribed with NVIDIA Parakeet · Why times can differ in your player
Yeah. Hi everyone, I'm Nikola Tangen, the CEO of the Norwegian Sovereign Wealth Fund, and today we have Thomas Schinneker, the CEO of Roche, which is one of the leading healthcare companies in the world. Rush. Was founded in eighteen ninety six, so it's uh really old. Lots of tradition have really innovated in uh healthcare. saved millions and millions of people and we are proud that we own two point three percent of the company worth
More than six billion dollars. So uh big thanks, Thomas, for joining us today. Thank you very much for the invitation. So Thomas, when um you drive into Basel, right, you have uh Rosh on one side of the river, Novartis On the other side of the river, two of the leading farmer companies in the world. So how come that this uh little Swiss town has grown to become one of the supercenters for biopharma.
I think it's all in the history of that region. uh starting with the chemical industry and then later moving into the pharma uh part of the industry. Uh so I I think it's all basically in the history of of the region. And located in the center of Europe, uh, it's actually quite ideally located. In addition.
We already have this episode, so unlocking it is cheap and permanent: the full transcript (54 minutes, 8,913 words), segment and word-level timestamps, and .txt, .srt, .vtt and word-level JSON downloads, as many times as you like, forever.
No account needed, we create one from your checkout email. With credits it is 1 credit; packs start at 5 episodes for $3.49, and monthly plans are cheaper still.